skip to main content

S. 2512 (114th): Adding Zika Virus to the FDA Priority Review Voucher Program Act

The text of the bill below is as of Apr 14, 2016 (Passed Congress).


One Hundred Fourteenth Congress of the United States of America

2d Session

S. 2512

IN THE SENATE OF THE UNITED STATES

AN ACT

To expand the tropical disease product priority review voucher program to encourage treatments for Zika virus.

1.

Short title

This Act may be cited as the Adding Zika Virus to the FDA Priority Review Voucher Program Act.

2.

Expanding tropical disease product priority review voucher program to encourage treatments for Zika Virus Disease

Section 524(a)(3) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360n(a)(3)) is amended—

(1)

by redesignating subparagraph (R) as subparagraph (S);

(2)

in subparagraph (Q), by striking Filoviruses and inserting Filovirus Diseases; and

(3)

by inserting after subparagraph (Q) the following:

(R)

Zika Virus Disease.

.

Speaker of the House of Representatives

Vice President of the United States and President of the Senate